Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: A retrospective case series

Sun, Yanhong; Man, Xiao‐Yong; Xuan, Xiuyun; Huang, Changzheng; Shen, Ying; Lao, Limin

doi:10.1111/dth.15848

Cited by 14 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral tofacitinib has been proposed as a promising treatment option for patients with rosacea and rosacea-like dermatitis who have significant inflammatory erythema and pustules on the face and for whom conventional treatments have not been effective. 8,9 However, no case reports have specifically explored its effects on GR. Tofacitinib, a JAK-1/3 inhibitor, tends to have more adverse effects compared to abrocitinib, a highly selective JAK-1 inhibitor.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report

Ren,

Yang,

Teng

et al. 2023

CCID

View full text Add to dashboard Cite

Granulomatous rosacea (GR) is a rare inflammatory skin disease characterized by persistent, hard, yellow, brown, red, or fleshcolored papules, plaques, or nodules on the face. Limited data are available on patients treated for GR, with only case reports and case series published. Herein, we describe the case of a 53-year-old woman who presented to the hospital with persistent red to brown and pink patches on both cheeks accompanied by a burning sensation for one month. Histopathological examination of a cutaneous biopsy revealed granulomatous inflammation in focal areas. Both acid-fast and Periodic acid-Schiff staining were negative. The patient was diagnosed with GR based on her clinical presentation and laboratory test results. She was treated with abrocitinib, a JAK-1 inhibitor, for 20 weeks. This resulted in substantial improvement in her rash and the associated burning sensation. Subsequent follow-up visits indicated no adverse effects or relapses. Additionally, a literature review was conducted to compare with the current case, which concluded that abrocitinib is a viable treatment option for GR, exhibiting a relatively high safety profile with minimal side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report

Ren,

Yang,

Teng

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…Previous studies have indicated that the JAK1/3 inhibitor tofacitinib can treat rosacea with satisfactory results. However, these two publications contained only one case of steroid-induced rosacea, and not all patients received tofacitinib monotherapy; some patients also received adjuvant therapy with conventional drugs ( 1 , 18 ). All patients in the present study received abrocitinib monotherapy and presented with steroid-induced rosacea that had responded poorly to conventional therapy.…”

Section: Discussionmentioning

confidence: 99%

JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series

Xu,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundSteroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea.ObjectiveTo observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea.MethodsFour Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea.ResultsAbrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed.ConclusionThe JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea.

show abstract

“… 8 , 9 A small retrospective case series even reported on a beneficial effect of tofacitinib in rosacea. 10 …”

Section: Discussionmentioning

confidence: 99%

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib

Neudorfer¹,

Trautinger²,

Prillinger³

2023

JAAD Case Reports

View full text Add to dashboard Cite

Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: A retrospective case series

Cited by 14 publications

References 18 publications

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report

JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib

Contact Info

Product

Resources

About